Company Description
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.
Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Country | United States |
Founded | 1992 |
IPO Date | Aug 11, 2016 |
Industry | Diagnostics & Research |
Sector | Healthcare |
Employees | 5,900 |
CEO | August Troendle |
Contact Details
Address: 5375 Medpace Way Cincinnati, Ohio 45227 United States | |
Phone | 513 579 9911 |
Website | medpace.com |
Stock Details
Ticker Symbol | MEDP |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001668397 |
CUSIP Number | 58506Q109 |
ISIN Number | US58506Q1094 |
Employer ID | 32-0434904 |
SIC Code | 8731 |
Key Executives
Name | Position |
---|---|
Dr. August James Troendle M.D. | Chairman and Chief Executive Officer |
Jesse J. Geiger BBA, CPA | President |
Kevin M. Brady | Chief Financial Officer and Treasurer |
Susan E. Burwig BSN, MA | Executive Vice President of Operations |
Stephen P. Ewald J.D. | Chief Compliance Officer, General Counsel and Corporate Secretary |
Brandon Ebken | Chief Information Officer |
Lauren Morris | Associate Director of Investors Relations |
Todd Meyers | Vice President of Business Development and Marketing |
John T. Wynne MBA | Senior Vice President of Commercial Operations and Clinical Pharmacology Unit |
Reinilde Heyrman M.D. | Chief Medical Officer of Medical Department |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 22, 2024 | 10-Q | Quarterly Report |
Oct 21, 2024 | 8-K | Current Report |
Aug 23, 2024 | 144/A | Filing |
Aug 22, 2024 | 144 | Filing |
Aug 16, 2024 | 144 | Filing |
Aug 15, 2024 | 144 | Filing |
Aug 9, 2024 | 144 | Filing |
Aug 6, 2024 | 144 | Filing |
Jul 30, 2024 | 144 | Filing |
Jul 25, 2024 | 144 | Filing |